|
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Clinical research trials and Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer. Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer clinical trial. Human subjects often get the best healthcare possible for their Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer  Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
For Condition: Non-small cell lung cancer,malignant mesothelioma,pulmonary carcinoid tumor,lung metastases,Small Cell Lung Cancer,thymoma and thymic carcinoma
Status: No longer recruiting
Sponsor(s): Jonsson Comprehensive Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.
Details: OBJECTIVES: - Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies. - Determine the efficacy of this treatment, in terms of local control, in these patients. - Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients. OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours. Patients are followed at 1, 3, 6, and 12 months. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Diagnosis of a primary or secondary intrathoracic malignancy - Any cell type or origin - Involving the intrapulmonary, mediastinal, or pleural/chest wall - Inoperable primary or metastatic cancer to the lung - Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy, or radiotherapy) - Single or multiple lesions that are non-contiguous with vital structures or organs such as: - Trachea - Heart - Aorta - Great vessels - Esophagus - Less than 5 cm in largest dimension - Accessible via percutaneous transthoracic route PATIENT CHARACTERISTICS: Age: - Not specified Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Coagulation profile normal Renal: - Not specified PRIOR CONCURRENT THERAPY: - See Disease Characteristics
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RobertSuh, Study Chair, Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
Additional Information:
Study ID Numbers: CDR0000068889; UCLA-9908024,NCI-G01-2011
Study Start Date:
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00024076
Other Malignant Mesothelioma Studies:
1. Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
Related Studies:
Other malignant mesothelioma Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
|
|
|
|
|
|
|
|
